Median Technologies - The Imaging Phenomics Company

Harnessing the power of Imaging Phenomics

We’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

CEO’s message

Fredrik Brag talks about how we’re looking to change the game, to transform the landscape in which we work and create a new world of possibilities for biopharma companies and healthcare professionals alike. "Through its groundbreaking medical imaging solutions, Median Technologies is bringing imaging phenomics to Precision Medicine and patient care with high throughput cancer screening, more accurate diagnostics and individually targeted therapies. By directly focusing on the disease phenotype with imaging biomarkers, we allow the patient to benefit from the best adapted treatment with the least side effects [...]"

The Imaging Phenomics Company®

Learn more about iSee®, our platform for the management of images in oncology clinical trials and iBiopsy®, our imaging phenomics platform combining Artificial Intelligence, Cloud Computing and Big Data.

Watch

News

11 July 2019

Median Technologies Announces Preliminary H1 2019 Unaudited Financial Results

H1 2019 results validate the company’s 2018 strategic refocus. During the period, revenues increased by 19,6% to reach €4 million (€3.4 million in H1 2018). Net new booking reached €11 million and order backlog increased by 30% to €30.7 million (€23.7 million as of December 31, 2018). Cash and cash equivalents expected to be approximatively €7.9 million as of June 30, 2019, with significantly reduced burn rate.

8 July 2019

AG Mednet and Median Technologies Partnership Supports Global Clinical Trials Portfolio, Including Extensive Programs in China

Median Technologiesand AG Mednet have renewed their partnership to use AG Mednet’s global infrastructure for the collection, QC and delivery of medical images and ancillary data in support current and future clinical trials and programs. Median provides solutions and services for medical image analysis and management in oncology trials globally. AG Mednet works with global CROs, providing technology solutions for clinical trial adjudication and imaging.

28 June 2019

Financial Communications Schedule for the Second Half of 2019

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its half year results 2019.

21 May 2019

Median Technologies to attend the 2019 ASCO Annual Meeting, May 31 – June 4, 2019, McCormick Place, Chicago, IL, USA

Median Technologies, The Imaging Phenomics Company®, announced today that it will be exhibiting at the 2019 ASCO Annual Meeting, May 31 – June 4 at the McCormick Place, Chicago, IL, USA (exhibition dates: June 1-3).

15 May 2019

Ongoing negotiations with the European Investment Bank to conclude a loan financing agreement including the issuance of Warrants (BSA)

This loan financing agreement will enable Median Technologies to accelerate its investment programs for its iBiopsy® imaging phenomics platform for the coming years

Opinion

8 August 2018

New White Paper – Innovations in Cancer Screening

New White Paper – Innovations in Cancer Screening There has been great progress in the diagnosis and treatment of cancer in recent years,…

10 July 2018

Demystifying How Images Are Managed

Demystifying How Images Are Managed Between February 2017 and January 2018, ~41.4 million diagnostic imaging tests were performed in England[i]. That so many…

18 June 2018

ASCO 2018: Headlines and Highlights

ASCO 2018: Headlines and Highlights All eyes were on the American Society of Clinical Oncology (ASCO) Annual conference last week in Chicago watching…

15 May 2018

Immunotherapy Update: Recent Advances in CAR T-cell Therapy

Immunotherapy Update: Recent Advances in CAR T-cell Therapy As a measure of its promise, chimeric antigen receptor (CAR) T-cell therapy – where patients’…

14 March 2018

Industry Trends: AI Revolutionizes Imaging Analysis

Industry Trends: AI Revolutionizes Imaging Analysis The radiology industry is embracing artificial intelligence (AI) to enhance image analysis, and it’s having a profound impact…

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Ibiopsy®

Powering the phenomics revolution

We’re changing the game, transforming the landscape. We’re capturing the power of big data, cloud computing and artificial intelligence to create a new world of possibilities for biopharma compannies and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision and predictive medicine.

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824

Get in touch

china

Median Technologies
12/F Platinum Tower 233 Tai Cang Road Shanghai 200020 China

Tel +86 021 51757777

europe

Median Technologies HQ
Les Deux Arcs, Bât B 1800, route des Crêtes 06560 Valbonne France

Tel +33 (0)4 93 333 777

United States

Legal address
Median Technologies Inc.
C/O Pramex International 1251 Avenue of the Americas 3rd Floor New York NY 10020

Jobs at Median